Amarin Corporation plc (AMRN) Fair Value 2026

AMRN · Drug Manufacturers - General ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 5 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-28, Amarin Corporation plc (AMRN) trades at $13.97, versus a $15.74 median fair value across its 5 active models — 12.7% above the current price. QOC: 6.1/10. Value Trap Risk: 34/100 (LOW). 5/13 models active. Within that set, the Bayesian DCF component alone returns $8.08.

Key Facts

Ticker
AMRN
Price
$13.97
Quality Score
6.1/10
Value Trap Risk
34/100
Models Active
5/13
Last Updated
Strength: CUCE Ensemble suggests +12.7% upside with 11% confidence
Risk: Limited model coverage (5/13) may reduce confidence

Is Amarin Corporation plc (AMRN) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, Amarin Corporation plc (AMRN) appears undervalued as of : the median of 5 independent fair value estimates is $15.74, 12.7% above the current price of $13.97. Estimates range from $8.08 to $35.37. AMRN scores 6.1/10 on fundamental quality and 34/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. AMRN’s +12.7% gap is narrower than that market norm, and the Drug Manufacturers - General sector median is +30.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Amarin Corporation plc Stock in 2026? →

What Fair Value Does Each Model Give AMRN?

5 Intrinsic Value Models vs. Current Price ($13.97)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $8.08 -42.2%
Ensemble · Low Conviction
 $15.74 +12.7%
Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, FTNN Topology, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is AMRN's Fair Value Range?

Spread across 5 independent models · $8.08 to $35.37

CirclFi's 5 active models place Amarin Corporation plc (AMRN) between $8.08 and $35.37 per share, a spread of 173% of the median. The median of that range — $15.74 — is the fair value CirclFi publishes for AMRN, against a current price of $13.97.

Low · Bayesian DCFHigh · FTNN
$8.08median $15.74$35.37
Where the range comes from
Most bearish modelBayesian DCF$8.08
Most bullish modelFTNN Topology$35.37
Model agreement3 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for AMRN. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on AMRN, not a CirclFi price target. How each model works →

What Is Amarin Corporation plc (AMRN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Amarin Corporation plc's intrinsic value is estimated at $15.74, suggesting a +12.7% median upside from the current price of $13.97. While 3 models see room for appreciation, model agreement is not unanimous as 2 models flag potential overvaluation. Model dispersion is worth noting: FTNN targets $35.37 (+153.2%), versus Bayesian DCF at $8.08 (-42.2%). This +195.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About AMRN?

5 of 13 models are currently active for AMRN. Of these, 3 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for AMRN is $15.74 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $8.08 on its own, implying -42.2% downside from the current price. See which stocks rank higher →

How Does AMRN Rank in Drug Manufacturers - General?

Among 21 Drug Manufacturers - General stocks, AMRN ranks #16 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

Amarin Corporation plc's positioning within the Drug Manufacturers - General segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.

Is AMRN a Value Trap?

CirclFi's Value Trap algorithm assigns AMRN a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for Amarin Corporation plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Amarin Corporation plc earns a quality score of 6.1/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +195.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AMRN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AMRN's 5 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Amarin Corporation plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - General Stocks Should You Also Analyze?

11 related Drug Manufacturers - General stocks with 13-model coverage

GRFSGrifols, S.A.QOC 6.9SCLXScilex Holding CompanyQOC 5.2OGNOrganon & Co.QOC 7.3MIRAMIRA Pharmaceuticals, Inc.QOC 4.7PFEPfizer Inc.QOC 7.5MDCXMedicus Pharma Ltd.QOC 4.0NSRXNasus Pharma Ltd.QOC 2.7AZNAstraZeneca PLCQOC 9.3BIIBBiogen Inc.QOC 7.9GILDGilead Sciences, Inc.QOC 9.7MRKMerck & Co., Inc.QOC 9.6

Read investment analysis: GRFS · SCLX · OGN · MIRA · PFE · MDCX · NSRX · AZN · BIIB · GILD · MRK

Which Other Stocks Have a Similar Quality Score to AMRN?

7 companies across all industries closest to AMRN’s Quality of Company score of 6.1/10.

GHIGreystone Housing Impact Investors LPQOC 6.1IIIVi3 Verticals, Inc.QOC 6.1MCTACharming Medical LimitedQOC 6.1LCLNLincoln International, Inc.QOC 6.1TICTIC Solutions, Inc.QOC 6.1HTFLHeartflow, Inc.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GHI · IIIV · MCTA · LCLN · TIC · HTFL · NVDA

What Else Do Investors Ask About Amarin Corporation plc’s Valuation?

What is Amarin Corporation plc's intrinsic value in 2026?

CirclFi puts Amarin Corporation plc (AMRN)'s intrinsic value at $15.74 — the median of 5 independent model estimates as of 2026-08-28, ranging from $8.08 to $35.37. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $8.08 on its own. The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AMRN overvalued or undervalued right now?

At $13.97, 3 of 5 active models suggest AMRN may be undervalued, while 2 indicate potential overvaluation. The median of all 5 fair value estimates is $15.74, 12.7% above the current price of $13.97 — a consensus view that AMRN is undervalued. The assessment depends on which methodology best fits Amarin Corporation plc's business model in Drug Manufacturers - General.

What does a Quality of Company score of 6.1 mean for AMRN?

Amarin Corporation plc's QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AMRN?

CirclFi analyzes AMRN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on AMRN?

Of the 5 models currently active on AMRN, FTNN Topology is the most bullish at $35.37 per share, and Bayesian DCF is the most bearish at $8.08. CirclFi's published fair value for AMRN is the median of that range, $15.74, not either extreme. The gap between the two ends equals 173% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is AMRN a value trap in 2026?

Amarin Corporation plc's Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, Amarin Corporation plc (AMRN) has a median fair value of $15.74 — 12.7% above the current price of $13.97 — as of 2026-08-28.” Source: circlfi.com/stock/AMRN/ · Methodology
Primary sources for this AMRN valuation
  • Financial statements: Amarin Corporation plc 10-K and 10-Q filings on SEC EDGAR (CIK 0000897448) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AMRN as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on AMRN.

Unlock All 5 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for AMRN Unlock All 5 — $39/mo